Monographie - Oseltamivir - Stabilis 4.0

Viimane versioon :
08/05/2024

Viirusevastane ravim

Oseltamivir

Suukaudne lahus

Stabiilsust ravimpreparaadid

Stabiilsust mõjutavad tegurid

Stabiilsust mõjutavad faktorid

Sobimatus

Viited

Pdf

Keemiline struktuur

Suukaudne lahus

Viited

Suukaudne lahus

Viited : Oseltamivir

	Tüüp	Avaldamine
2692	Ajaleht	Winiarski AP, Infeld MH, Tscherne R, Bachinsky M, Rucki R, Nagano-Mate K. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc 2007 ; 47, 6; 747-755.
3090	Ajaleht	Voudrie MA, Brett Allen D. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution). Int J Pharm Compound 2010 ; 14, 1: 82-85.
3996	Ajaleht	Dijkers E,Nanhekhan V,Thorissen A. Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSprend SF and Minoxidil in Espumil. Int J Pharm Compound 2017 ; 21,3 : 240-241.
4177	Ajaleht	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526

Mentions Légales